4DMedical Ltd (AU:4DX) has released an update.
4DMedical Ltd, a respiratory imaging technology firm, has seen a significant 422% increase in operating revenue to $3.8 million for FY2024, driven primarily by Software-as-a-Service sales. The company has strategically acquired AI medical imaging company Imbio, which is expected to become cash flow positive within the year. Additionally, new FDA approvals, CMS reimbursements, and commercial agreements, including a Teaming Agreement with Philips for U.S. VA commercialization, position 4DMedical for further growth.
For further insights into AU:4DX stock, check out TipRanks’ Stock Analysis page.